Last Update 08 Aug 26
Fair value Increased 19%ASPN: Improved Segment Visibility And Restart Progress May Support Future Upside
Analysts have lifted the fair value estimate for Aspen Aerogels from $6.35 to $7.55, citing higher modeled revenue growth, a slightly stronger long term profit margin profile, and recent Street research pointing to better visibility across both operating segments after the latest quarterly updates.
Analyst Commentary
Recent Street research on Aspen Aerogels points to higher conviction around the company’s outlook following the latest quarterly update. Investors are weighing how this improved visibility across both operating segments might influence execution risk and the fair value range for the stock.
Bullish Takeaways
- Bullish analysts point to improved visibility in both operating segments after the Q2 report, which they see as supportive of more reliable revenue modeling and cash flow forecasts.
- Higher published price targets, including a move to US$9, suggest that some analysts view Aspen Aerogels as having additional upside potential relative to recent trading levels, based on their current growth and margin assumptions.
- Street commentary highlights a more confident view on the long term profit margin profile, which feeds directly into higher fair value estimates and reflects expectations for better operating leverage over time.
- The cluster of recent positive revisions is viewed by some investors as a sign that execution risk on current growth plans may be lower than previously feared, even if the timing and scale of outcomes remain uncertain.
Bearish Takeaways
- Even with higher price targets, some cautious analysts may see limited room for error, since the updated fair value estimates already factor in stronger revenue growth and margin assumptions that Aspen Aerogels still needs to deliver on.
- Improved segment visibility is based on the most recent quarterly data, so any slowdown in order activity or project timing could challenge current valuation frameworks built into these new targets.
- The reliance on modeled long term margin improvement introduces execution risk, particularly if cost control, capacity utilization, or pricing do not track current Street assumptions.
- As more optimistic views become reflected in valuation, investors who are cautious may focus on the potential for sentiment to reverse if future quarterly results do not align with the upgraded expectations for Aspen Aerogels.
What’s in the News for Aspen Aerogels
- Aspen Aerogels issued earnings guidance for the third quarter ending September 30, 2026, with expected revenue in a range of US$65 million to US$80 million. The company projected a net loss between US$6 million and US$9 million, or a net loss per share between US$0.07 and US$0.11. (Source: Key Developments)
- The company reported the successful initiation of a staged restart of manufacturing operations at its East Providence, Rhode Island facility, following an incident on April 8. Aspen Aerogels completed mechanical, operational, and safety reviews with local, state, and federal agencies, carried out equipment inspections and safety checks, and is now pursuing a deliberate, phased ramp up of production. The company noted that returning to full capabilities will take time. (Source: Key Developments)
Valuation Changes for Aspen Aerogels
- Fair Value has risen from $6.35 to $7.55, which is an increase of about 19% in the modeled estimate.
- Discount Rate has edged higher from 7.65% to about 7.66%, a very small change in the risk assumption used in the model.
- Revenue Growth has been raised from 17.91% to about 29.80%, which is a large uplift in the projected topline growth rate for Aspen Aerogels.
- Net Profit Margin has moved slightly higher from 9.10% to about 9.16%, reflecting a modest adjustment to long term profitability assumptions.
- Future P/E has been adjusted from 19.36x to about 19.56x, a small change in the earnings multiple applied in the updated valuation framework.
Key Takeaways
- Cost reductions and process improvements are enhancing profitability and positioning the company for stronger earnings even at modest revenue levels.
- Strategic focus on EV thermal barriers and U.S.-based manufacturing aligns with regulatory trends, supporting future growth and market share expansion.
- Heavy reliance on key segments and customers, regulatory uncertainty, and ongoing margin pressures threaten growth projections and create revenue and earnings vulnerability.
Catalysts
About Aspen Aerogels- An aerogel technology company, designs, develops, manufactures, and sells aerogel materials primarily for use in the energy industrial, sustainable insulation materials, and electric vehicle (EV) markets in the United States, Canada, Asia, Europe, and Latin America.
- Aspen's cost optimization-reducing fixed costs by ~$65M and streamlining operations-substantially lowers the revenue threshold needed to achieve profitability. This greater operating leverage, combined with a stable cost structure and controlled CapEx, is set to significantly improve EBITDA and net margin even at modest revenue recovery.
- Medium-term visibility into a rebound in project-based Energy Industrial revenues (subsea/LNG), as key customers' 2025 wins and robust project backlogs are expected to drive attractive incremental revenue and high gross margins from 2026 onwards.
- Strong positioning in the EV thermal barrier market with major OEMs like GM, Stellantis, and Daimler, alongside active new quoting and prototyping activities, underpins a path toward multi-year revenue acceleration as electrification in transportation and strict emissions regulations continue to ramp up globally.
- Ongoing process improvements and increased production efficiency at the Rhode Island and Mexico facilities are driving productivity gains and gross margin expansion, further boosting long-term earnings power and resilience to lower EV production volatility.
- Domestic manufacturing capacity and flexible sourcing strategies cater to automaker preferences for U.S.-based supply and position Aspen as a preferred supplier amid intensifying regulations favoring energy efficiency and sustainability, supporting long-term revenue growth and market share gains.
Aspen Aerogels Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Aspen Aerogels's revenue will grow by 29.8% annually over the next 3 years.
- Analysts are not forecasting that Aspen Aerogels will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Aspen Aerogels's profit margin will increase from -62.4% to the average US Chemicals industry of 9.2% in 3 years.
- If Aspen Aerogels's profit margin were to converge on the industry average, you could expect earnings to reach $40.5 million (and earnings per share of $0.48) by about August 2029, up from -$126.2 million today.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.7x on those 2029 earnings, up from -4.1x today. This future PE is lower than the current PE for the US Chemicals industry at 26.9x.
- Analysts expect the number of shares outstanding to grow by 0.65% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.66%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Slower-than-expected demand recovery in the Energy Industrial segment, with continued destocking by distributors and delayed project activity (especially in subsea and LNG markets), exposes Aspen to prolonged revenue weakness and challenges the assumption of strong growth in this core business.
- High customer concentration in the EV Thermal Barrier segment, particularly reliance on GM, poses a risk to future revenues and earnings if GM's EV production or market share stalls or declines, as suggested by management noting production levels tracking IHS forecasts and emphasizing GM's outsized impact.
- Ongoing policy and regulatory volatility in key markets (notably the U.S. EV market) create uncertainty for EV adoption rates and timing of OEM launches, potentially undermining anticipated topline growth and slowing earnings improvement.
- Adjacent OEM programs, design-in activity, and new platform launches outside of current key customers (e.g., Daimler, Stellantis, ACC) have uncertain timelines or significant slippage due to shifting automaker plans and reaction to changing government incentives, posing risk to the realization of outsized growth projections for 2026-2027.
- The need for persistent R&D and capital expenditures to remain competitive combined with achieved cost reductions cycling out of the base may limit further margin expansion, while risks such as commodity price volatility and potential industry-wide pricing pressure could negatively impact future gross margins and net income.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $7.55 for Aspen Aerogels based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $10.0, and the most bearish reporting a price target of just $4.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $441.9 million, earnings will come to $40.5 million, and it would be trading on a PE ratio of 19.7x, assuming you use a discount rate of 7.7%.
- Given the current share price of $6.25, the analyst price target of $7.55 is 17.2% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Aspen Aerogels?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.